Literature DB >> 20088754

The structure and functions of P-glycoprotein.

Y Li1, H Yuan, K Yang, W Xu, W Tang, X Li.   

Abstract

P-glycoprotein (P-gp) is an ATP-driven transmembrane transporter capable of effluxing a wide variety of structurally diverse and functionally unrelated hydrophobic compounds out of the cell. Multidrug resistance (MDR), often associated with the over-expression of P-gp, has been implicated as a major obstacle to effective chemotherapy for cancer, parasitic diseases, AIDS, and other diseases. Drug efflux mediated by P-gp is also involved in decreasing the oral bioavailability of drugs by limiting intestinal absorption. Our appreciation of the structural and functional aspects of P-gp has definitely improved in recent years, benefiting from the deciphering of the structure of some bacterial transporters that paved the way for construction of homology models for more complex transporters. Here, we will review the recent advances in the studies of the structure and functional characteristics of P-gp with the hopes of facilitating rational drug design in developing novel potent MDR modulators.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088754     DOI: 10.2174/092986710790514507

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  19 in total

1.  Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Authors:  Haiyang Chen; Kazuhiko Shien; Ken Suzawa; Kazunori Tsukuda; Shuta Tomida; Hiroki Sato; Hidejiro Torigoe; Mototsugu Watanabe; Kei Namba; Hiromasa Yamamoto; Junichi Soh; Hiroaki Asano; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

2.  Filamin-A as a marker and target for DNA damage based cancer therapy.

Authors:  Jingyin Yue; Huimei Lu; Jingmei Liu; Marianne Berwick; Zhiyuan Shen
Journal:  DNA Repair (Amst)       Date:  2011-11-02

Review 3.  Emerging role for drug transporters at the blood-testis barrier.

Authors:  Dolores D Mruk; Linlin Su; C Yan Cheng
Journal:  Trends Pharmacol Sci       Date:  2010-12-17       Impact factor: 14.819

Review 4.  Drug transporters, the blood-testis barrier, and spermatogenesis.

Authors:  Linlin Su; Dolores D Mruk; C Yan Cheng
Journal:  J Endocrinol       Date:  2010-12-06       Impact factor: 4.286

5.  Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells.

Authors:  Soo-Jung Park; Khadijeh Bijangi-Vishehsaraei; Ahmad R Safa
Journal:  Int J Biochem Mol Biol       Date:  2010-07-18

6.  Methylation of SFRP5 is related to multidrug resistance in leukemia cells.

Authors:  H Wang; X Wang; R Hu; W Yang; A Liao; C Zhao; J Zhang; Z Liu
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

7.  Structural basis for substrate specificity in the Escherichia coli maltose transport system.

Authors:  Michael L Oldham; Shanshuang Chen; Jue Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

8.  Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line.

Authors:  Hui-Han Wang; Ying-Chun Li; Ai-Jun Liao; Bei-Bei Fu; Wei Yang; Zhuo-Gang Liu; Xiao-Bin Wang
Journal:  Chin J Cancer Res       Date:  2011-03       Impact factor: 5.087

9.  MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.

Authors:  Qi Liu; Changyuan Wang; Qiang Meng; Xiaokui Huo; Huijun Sun; Jinyong Peng; Xiaochi Ma; Pengyuan Sun; Kexin Liu
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

10.  Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.

Authors:  Yinghui Chen; Yongbo Zhao; Cuicui Wang; Xia Xiao; Xiaoyong Zhou; Guoxiong Xu
Journal:  Med Sci Monit       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.